Document Detail


The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study.
MedLine Citation:
PMID:  22702640     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Macrolides are a group of commonly prescribed antibiotics. There is some doubt surrounding the use of the newer macrolides in pregnancy.
OBJECTIVE: The present study aimed to compare outcomes of pregnancies exposed to the new macrolides clarithromycin, azithromycin and roxithromycin with non-teratogenic preparations.
METHODS: In this prospective, multinational, multicentre, controlled, observational study, information was obtained either from pregnant women or their healthcare professionals who contacted their local teratogen information services in Italy, Israel, the Czech Republic, the Netherlands and Germany seeking information after exposure to macrolides. The comparison group included women or their healthcare professional who contacted these centres with questions regarding known non-teratogenic preparations. Information on obstetric and other background parameters was collected at enrollment; after delivery, subjects or their healthcare professionals were contacted to ascertain pregnancy outcome parameters and other exposures through the remainder of the pregnancy.
RESULTS: A total of 608 women exposed to macrolides during pregnancy were enrolled; 511 of the exposures occurred during the first trimester. The comparison group comprised 773 women exposed to non-teratogenic preparations during the first trimester of pregnancy. No significant difference in the rate of major congenital malformations was found between the study group and the comparison group (3.4% vs 2.4%; p = 0.36; odds ratio (OR) 1.42; 95% CI 0.70, 2.88) or in the rate of cardiovascular malformations (1.6% vs 0.9%; p = 0.265; OR 1.91; 95% CI 0.63, 5.62). No significant differences were found between subgroups of macrolides in the rates of major congenital malformations or cardiac malformations, although for azithromycin this was of borderline significance.
CONCLUSIONS: This study, in agreement with earlier smaller studies, suggests that the new macrolides do not pose a significantly increased risk of major congenital malformations or cardiac malformations.
Authors:
Benjamin Bar-Oz; Corinna Weber-Schoendorfer; Maya Berlin; Maurizio Clementi; Elena Di Gianantonio; Loes de Vries; Marco De Santis; Paul Merlob; Bracha Stahl; Giorgio Eleftheriou; Eva Maňáková; Lucie Hubičková-Heringová; Ilan Youngster; Matitiahu Berkovitch
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Drug safety     Volume:  35     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-18     Completed Date:  2012-10-23     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  589-98     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / etiology*
Adolescent
Adult
Anti-Bacterial Agents / adverse effects*
Europe
Female
Humans
Macrolides / adverse effects*
Maternal-Fetal Exchange
Pregnancy
Pregnancy Complications*
Pregnancy Outcome
Pregnancy Trimester, First
Prenatal Exposure Delayed Effects / chemically induced*
Prospective Studies
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Macrolides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenou...
Next Document:  A signal detection method to detect adverse drug reactions using a parametric time-to-event model in...